CN110226630B - 缓解pfoa毒害作用的多功能布氏乳杆菌ccfm1053、其发酵食品及应用 - Google Patents
缓解pfoa毒害作用的多功能布氏乳杆菌ccfm1053、其发酵食品及应用 Download PDFInfo
- Publication number
- CN110226630B CN110226630B CN201910575089.7A CN201910575089A CN110226630B CN 110226630 B CN110226630 B CN 110226630B CN 201910575089 A CN201910575089 A CN 201910575089A CN 110226630 B CN110226630 B CN 110226630B
- Authority
- CN
- China
- Prior art keywords
- pfoa
- ccfm1053
- lactobacillus buchneri
- mice
- fermented food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186679 Lactobacillus buchneri Species 0.000 title claims abstract description 67
- SNGREZUHAYWORS-UHFFFAOYSA-N perfluorooctanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F SNGREZUHAYWORS-UHFFFAOYSA-N 0.000 title claims abstract 9
- 235000021107 fermented food Nutrition 0.000 title claims description 18
- 231100000331 toxic Toxicity 0.000 title claims description 7
- 230000002588 toxic effect Effects 0.000 title claims description 7
- 206010010774 Constipation Diseases 0.000 claims abstract description 20
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 8
- 235000013365 dairy product Nutrition 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 231100000419 toxicity Toxicity 0.000 claims description 5
- 230000001988 toxicity Effects 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 4
- 240000007087 Apium graveolens Species 0.000 claims description 3
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims description 3
- 235000010591 Appio Nutrition 0.000 claims description 3
- 235000016068 Berberis vulgaris Nutrition 0.000 claims description 3
- 241000335053 Beta vulgaris Species 0.000 claims description 3
- 240000007124 Brassica oleracea Species 0.000 claims description 3
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 3
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 3
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims description 3
- 240000008067 Cucumis sativus Species 0.000 claims description 3
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims description 3
- 244000000626 Daucus carota Species 0.000 claims description 3
- 235000002767 Daucus carota Nutrition 0.000 claims description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 3
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 3
- 235000015142 cultured sour cream Nutrition 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 235000021056 liquid food Nutrition 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 235000021055 solid food Nutrition 0.000 claims description 3
- 235000013351 cheese Nutrition 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims 1
- 230000004151 fermentation Effects 0.000 claims 1
- 235000013402 health food Nutrition 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 20
- 230000014509 gene expression Effects 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 15
- 210000000952 spleen Anatomy 0.000 abstract description 13
- 210000004185 liver Anatomy 0.000 abstract description 12
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 abstract description 10
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 abstract description 10
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 abstract description 10
- 230000000968 intestinal effect Effects 0.000 abstract description 10
- 208000019423 liver disease Diseases 0.000 abstract description 9
- 206010003694 Atrophy Diseases 0.000 abstract description 8
- 102100023374 Forkhead box protein M1 Human genes 0.000 abstract description 8
- 101000907578 Homo sapiens Forkhead box protein M1 Proteins 0.000 abstract description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 8
- 230000037444 atrophy Effects 0.000 abstract description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 7
- 101150084866 MAFA gene Proteins 0.000 abstract description 7
- 230000035755 proliferation Effects 0.000 abstract description 7
- 230000009471 action Effects 0.000 abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 abstract description 3
- 108010082126 Alanine transaminase Proteins 0.000 abstract description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 abstract description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 abstract description 3
- 230000013872 defecation Effects 0.000 abstract description 3
- 239000008187 granular material Substances 0.000 abstract description 3
- 101100129232 Danio rerio mafaa gene Proteins 0.000 abstract description 2
- 101150051019 Klrg1 gene Proteins 0.000 abstract description 2
- SNGREZUHAYWORS-UHFFFAOYSA-M 2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoate Chemical compound [O-]C(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F SNGREZUHAYWORS-UHFFFAOYSA-M 0.000 description 76
- 241000699670 Mus sp. Species 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 241000606125 Bacteroides Species 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 239000000047 product Substances 0.000 description 14
- 238000001179 sorption measurement Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical group C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000003608 fece Anatomy 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241001052560 Thallis Species 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 208000028774 intestinal disease Diseases 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229960004586 rosiglitazone Drugs 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000004807 desolvation Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- -1 perfluoro compound Chemical class 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010016100 Faeces discoloured Diseases 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 241001462463 Lactobacillus plantarum ST-III Species 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 2
- 229960001571 loperamide Drugs 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000002068 microbial inoculum Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001467578 Microbacterium Species 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- DZKZCXUIXLRBSY-UHFFFAOYSA-N Oc1ccc2oc(O)c(-c3ccccc3)c(=O)c2c1O Chemical compound Oc1ccc2oc(O)c(-c3ccccc3)c(=O)c2c1O DZKZCXUIXLRBSY-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 101100396999 Rattus norvegicus Ins1 gene Proteins 0.000 description 1
- 206010074268 Reproductive toxicity Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000007673 developmental toxicity Effects 0.000 description 1
- 231100000415 developmental toxicity Toxicity 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- SAMRUMKYXPVKPA-UHFFFAOYSA-N n-[1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]docosanamide Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1C1C(O)C(O)C(CO)O1 SAMRUMKYXPVKPA-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000007696 reproductive toxicity Effects 0.000 description 1
- 231100000372 reproductive toxicity Toxicity 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C13/00—Cream; Cream preparations; Making thereof
- A23C13/12—Cream preparations
- A23C13/16—Cream preparations containing, or treated with, microorganisms, enzymes, or antibiotics; Sour cream
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C20/00—Cheese substitutes
- A23C20/02—Cheese substitutes containing neither milk components, nor caseinate, nor lactose, as sources of fats, proteins or carbohydrates
- A23C20/025—Cheese substitutes containing neither milk components, nor caseinate, nor lactose, as sources of fats, proteins or carbohydrates mainly containing proteins from pulses or oilseeds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/20—Products from fruits or vegetables; Preparation or treatment thereof by pickling, e.g. sauerkraut or pickles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了缓解PFOA毒害作用的多功能布氏乳杆菌CCFM1053、其发酵食品及应用，本发明所述布氏乳杆菌CCFM1053能够吸附PFOA、改善因PFOA暴露造成的脾脏萎缩、升高PFOA暴露后血清中TNF‑α含量、升高PFOA暴露小鼠血清中谷丙转氨酶、谷草转氨酶、γ‑谷氨酰转肽酶的含量、将PFOA暴露后肝脏中MDA的含量降低到正常水平、降低GSH活性、改善肠道菌群紊乱、减少肝病的发生、提高便秘患者的粪便含水量和首粒排黑便时间、缓解便秘、提高高糖作用下INS‑1细胞的增殖和MafA基因的表达、缓解PFOA相关糖尿病。
Description
技术领域
本发明属于微生物技术领域，具体涉及缓解PFOA毒害作用的多功能布氏乳杆菌CCFM1053、其发酵食品及应用。
背景技术
全氟化合物由于其疏水疏油特性，并且具有良好的热稳定性，化学稳定性和生物稳定性，在各行各业受到了广泛的应用。用于成衣(如防水，防污户外服饰)及家居纺织品(如地毯，家具布料等)，外卖食品容器，个人护理产品(如牙线)以及灭火泡沫等等。而其中PFOA作为是多种氟类化合物的最终转化产物之一，可以随着食物链富集。在全球各种环境介质，例如水，土壤，大气层，灰尘等，以及动物人体内中均检测到PFOA的存在，并且在人体内的半衰期为2-3年，因此受到了研究学者越来越多的重视。在2013年就作为持久，累积和毒性化学物质被《化学品注册、评估、授权和限制法规》(REACH法规)纳入《高度关注物质候选名单》，在2017年正式列入REACH法规，在欧盟各国实施限制。然而，在部分国家PFOA仍在大量使用，且环境中残留的PFOA还会在未来很长一段时间对整个生态系统造成持久影响。
暴露人群血液中PFOA含量与可能的健康影响之间的关联研究发现，暴露于PFOA可能与血液中总胆固醇浓度的升高，肝酶ALT浓度上升与出生体重降低有较明显的关系。而且已经发现PFOA暴露与疫苗接种反应减少存在关联。这些迹象表明，PFOA可能影响人体的肝脏功能，脂代谢与免疫功能。而在人体中出现的影响在哺乳动物体内已经被明确发现，PFOA具有肝脏毒性，免疫毒性，生殖毒性，发育毒性，神经毒性等多种毒性作用。PFOA可以导致肝肿大，同时可诱发小鼠肝组织氧化应激，使自由基异常增多，可能是造成肝脏损伤的主要原因。PFOA暴露对水生动物和啮齿动物免疫系统的多个免疫器官均产生不同程度的损伤，造成免疫器官脾脏和胸腺的萎缩老化，明显干扰斑马鱼脾脏白介素的表达，淋巴细胞的凋亡与衰退。在对哮喘小鼠的暴露实验中，高剂量PFOA暴露相对哮喘模型组外周血炎症因子IL-4升高，IFN-γ明显较低，即诱导Th2型免疫反应加剧肺部炎症。
目前缓解PFOA毒性的方法多是从具有高抗氧化活性的天然化学物质着手，研究中有缓解作用的如枸杞多糖、桑色素、三羟异黄酮、番茄红素等。但这些天然物质都存在价格昂贵且难以获得，此外由于人体的承受能力，大量的摄入对人体是否存在的潜在危害尚不得知。因此，寻找一种能够有效缓解PFOA毒性，并且对人体不存在其他可能的有害作用的有效方法显然十分有必要。
发明内容
本部分的目的在于概述本发明的实施例的一些方面以及简要介绍一些较佳实施例。在本部分以及本申请的说明书摘要和发明名称中可能会做些简化或省略以避免使本部分、说明书摘要和发明名称的目的模糊，而这种简化或省略不能用于限制本发明的范围。
鉴于上述的技术缺陷，提出了本发明。
因此，作为本发明其中一个方面，本发明克服现有技术中存在的不足，提供布氏乳杆菌CCFM1053，保藏编号为GDMCC No：60651。
作为本发明的另一个方面，本发明克服现有技术中存在的不足，提供一种发酵食品：所述发酵食品为使用布氏乳杆菌CCFM1053发酵生产制得，所述发酵食品包括固态食品、液态食品、半固态食品。
作为本发明所述的发酵食品的一种优选方案：所述发酵食品包括乳制品、豆制品、果蔬制品，所述乳制品包括牛奶、酸奶油、干酪；所述果蔬制品包括黄瓜、胡萝卜、甜菜、芹菜、圆白菜制品。
作为本发明的另一个方面，本发明克服现有技术中存在的不足，提供布氏乳杆菌CCFM1053在制备体内非定植益生菌中的应用。
作为本发明的另一个方面，本发明克服现有技术中存在的不足，提供布氏乳杆菌CCFM1053在制备缓解PFOA的毒性作用、治疗及预防便秘和抗肝病的药物和保健品中的应用。
作为本发明所述的应用的一种优选方案：所述布氏乳杆菌CCFM1053能够吸附PFOA、改善因PFOA暴露造成的脾脏萎缩、升高PFOA暴露后血清中TNF-α含量、升高PFOA暴露后血清中谷丙转氨酶(ALT)、谷草转氨酶(AST)、γ-谷氨酰转肽酶(γ-GT)的含量、将PFOA暴露后肝脏中MDA的含量降低到正常水平、降低GSH活性、改善肠道菌群紊乱、降低肠道中Alobaculum属的丰度，升高拟杆菌属(Bacteroides)和Eubacteriaceae科的丰度、减少肝病的发生、提高便秘患者的粪便含水量和首粒排黑便时间、缓解便秘。所述布氏乳杆菌CCFM1053还能够提高高糖作用下INS-1细胞的增殖和MafA基因的表达、缓解PFOA相关糖尿病。
作为本发明的另一个方面，本发明克服现有技术中存在的不足，提供所述的发酵食品在制品缓解PFOA毒性、预防和治疗便秘、抗肝病的功能性食品中的应用。
本发明的有益效果：本发明所述布氏乳杆菌CCFM1053能够吸附PFOA、改善因PFOA暴露造成的脾脏萎缩、升高PFOA暴露后血清中TNF-α含量、升高PFOA暴露后血清中谷丙转氨酶(ALT)、谷草转氨酶(AST)、γ-谷氨酰转肽酶(γ-GT)的含量、将PFOA暴露后肝脏中MDA的含量降低到正常水平、降低GSH活性、改善肠道菌群紊乱、降低肠道中Alobaculum属的丰度，升高拟杆菌属(Bacteroides)和Eubacteriaceae科的丰度、减少肝病的发生、提高便秘患者的粪便含水量和首粒排黑便时间、缓解便秘。所述布氏乳杆菌CCFM1053还能够提高高糖作用下INS-1细胞的增殖和MafA基因的表达、缓解PFOA相关糖尿病。
附图说明
为了更清楚地说明本发明实施例的技术方案，下面将对实施例描述中所需要使用的附图作简单地介绍，显而易见地，下面描述中的附图仅仅是本发明的一些实施例，对于本领域普通技术人员来讲，在不付出创造性劳动性的前提下，还可以根据这些附图获得其它的附图。其中：
图1为本菌株在体外重悬于浓度为10mg/L PFOA中经过37℃，150rpm摇床6h后，过0.22μm水系滤膜进入超高效液相色谱质谱联用仪中，吸附前后PFOA浓度变化示意图。
图2为本菌株干预10天后小鼠暴露于PFOA，小鼠脾脏比的变化图。其中*P<0.05(vs模型组)。
图3为本菌株干预10天后小鼠暴露于PFOA，小鼠血清中ALT(图a)、AST(图b)、γ-GT(图c)水平示意图。其中*P<0.05，**P<0.01，***P<0.001，****P<0.0001(vs模型组)。
图4为本菌株干预10天后暴露于PFOA，小鼠肝脏中GSH活性和MDA含量的变化示意图。
图5为本菌株干预10天后小鼠暴露于PFOA，小鼠血清中肿瘤坏死因子α示意图。其中*P<0.05，**P<0.01(vs模型组)。
图6为本菌株干预10天后小鼠暴露于PFOA，小鼠肠道菌群α多样性变化示意图；其中*P<0.05，**P<0.01，***P<0.001(vs模型组)。
图7为本菌株干预10天后小鼠暴露于PFOA，小鼠肠道中Eubacteriaceae科、拟杆菌属(Bacteroides)和Alobaculum属丰度的变化示意图；其中*P<0.05，**P<0.01(vs模型组)。
图8为本菌株干预后便秘小鼠粪便含水量的改善情况；其中*P<0.05，**P<0.01，***P<0.001(vs模型组)。
图9为本菌株干预后便秘小鼠首粒黑便排出时间的降低情况；其中*P<0.05，**P<0.01，***P<0.001(vs模型组)。
图10是本菌株对高糖作用下INS-1细胞增值情况的影响。
图11是本菌株对高糖作用下INS-1细胞MafA基因表达的影响。
具体实施方式
为使本发明的上述目的、特征和优点能够更加明显易懂，下面结合具体实施例对本发明的具体实施方式做详细的说明。
在下面的描述中阐述了很多具体细节以便于充分理解本发明，但是本发明还可以采用其他不同于在此描述的其它方式来实施，本领域技术人员可以在不违背本发明内涵的情况下做类似推广，因此本发明不受下面公开的具体实施例的限制。
其次，此处所称的“一个实施例”或“实施例”是指可包含于本发明至少一个实现方式中的特定特征、结构或特性。在本说明书中不同地方出现的“在一个实施例中”并非均指同一个实施例，也不是单独的或选择性的与其他实施例互相排斥的实施例。
本发明的布氏乳杆菌CCFM1053，保藏于广东省微生物菌种保藏中心，保藏编号为GDMCC No：60651。
所述布氏乳杆菌具有以下生物学特性：
(1)菌体特征：革兰氏阳性，细胞球状，直径0.8～1.0μm，无鞭毛，无芽孢；
(2)菌落特征：菌落乳白色，边缘整齐，球状，凸起，不透明，表面湿润光滑；
(3)生长特性：该菌株的最低生长温度为15℃，最高生长温度为45℃，在温度35-37℃下生长最佳，最适生长pH为6.5，培养18h后进入稳定期；
(4)体外具有良好的PFOA吸附能力；
(5)布氏乳杆菌CCFM1053能显著改善PFOA暴露小鼠脾脏萎缩；
(6)布氏乳杆菌CCFM1053能显著降低PFOA暴露小鼠血清中ALT、AST、γ-GT的水平；
(7)布氏乳杆菌CCFM1053能显著降低PFOA暴露小鼠肝脏中MDA和GSH的水平。
(8)布氏乳杆菌CCFM1053能够显著降低PFOA暴露小鼠血清中TNF-α的含量；
(9)布氏乳杆菌CCFM1053能显著降低PFOA暴露小鼠肠道中的丰度Alobaculum属的丰度，提高拟杆菌属(Bacteroides)和优杆菌科(Eubacteriaceae)丰度，改善PFOA暴露造成的肠道紊乱，减少肝病的发生。
(10)布氏乳杆菌CCFM1053能显著提高便秘小鼠的粪便含水量和首粒黑便排出时间，缓解小鼠的便秘情况。
(11)布氏乳杆菌CCFM1053能够显著改善高糖作用下INS-1细胞的增殖和MafA基因的表达，缓解PFOA相关糖尿病。
所述布氏乳杆菌CCFM1053的提取方法为：
(一)乳酸菌的分离筛选：
(l)取100μL泡菜水。将样品在含有山梨醇MRS培养基中35℃富集12h；
(2)将富集样品进行梯度稀释后涂布于添加了0.02％嗅甲酚紫的MRS固体平板上，培养24-48h；
(3)选取变色圈明显，并且符合乳酸菌基本形态的单菌落进行平板划线纯化，筛选分离出乳酸菌；
(4)将上述单菌落培养于液体MRS培养液中培养24h后进行革兰氏染色，选取革兰氏阳性菌进行后续试验。
(二)乳杆菌的初步鉴定：溶钙圈测定法
(l)将步骤(一)所筛选得到的乳酸菌在液体山梨醇MRS培养液中培养24h，然后取lmL培养物8000rpm离心2min；
(2)用0.05M KH2PO4溶液洗涤两次；
(3)将所得菌泥重悬，划线在山梨醇MRS-0.75％CaCO3的固体培养基上，培养24h；
(4)选取溶钙圈明显，且呈凸面圆形、细密色白、无菌丝体的菌落，革兰氏染色后显微镜观察菌体为杆状即初步判定为乳杆菌。
(三)布氏乳杆菌的分子生物学鉴定：
(l)单菌基因组抽提：
A.将步骤(二)所筛选得到的乳酸菌培养过夜，取培养过夜的菌悬液l mL于1.5mL离心管，10000rpm离心2min，弃上清得菌体；
B.用l mL无菌水吹洗菌体后，10000rpm离心2min，弃上清得菌体；
C.加入200μLSDS裂解液，80℃水浴30min；
D.加入酚-氯仿溶液200μL于菌体裂解液中，其中酚-氯仿溶液的组成成分及体积比为Tris饱和酚:氯仿:异戊醇＝25:24:1，颠倒混匀后，12000rpm离心5-10min，取上清200μL；
E.加入400μL冰乙醇或冰异丙醇于200uL上清中，﹣20℃静置1h，12000rpm离心5-10min，弃上清；
F.加入500μL70％(体积百分数)冰乙醇重悬沉淀，12000rpm离心1-3min，弃上清；
G.60℃烘箱烘干，或者自然晾干；
H.50μLddH2O重溶沉淀以备PCR；
(2)16S rDNA PCR
A.细菌16S rDNA 50μLPCR反应体系：
10×Taq buffer，5μL；dNTP，5μL；27F，0.5μL；1492R，0.5μL；Taq酶，0.5μL；模板，0.5μL；ddH2O，38μL。
B.PCR条件：
95℃5min；95℃10s；55℃30s；72℃30s；step2-4 30×；72℃5min；12℃2min；
(3)制备1％琼脂糖凝胶，之后将PCR产物与10×loadingbuffer混合，上样量5μL，120V跑30min，然后进行凝胶成像；
(4)将16S rDNA的PCR产物进行测序分析，将得到的序列结果使用BLAST在GeneBank中进行搜索和相似性比对，选取测序结果鉴定为属于布氏乳杆菌的一种新发现的菌株，-80℃保藏备用。
实施例1：布氏乳杆菌CCFM1053具有良好的PFOA吸附能力
菌体吸附对布氏乳杆菌CCFM1053进行纯化和活化培养，按1％(v/v)接种量接种于MRS液体培养基中，37℃培养18h。然后在8000r/min离心5min收集菌体，取沉淀用生理盐水清理后继续在8000r/min离心5min，去沉淀得到活菌体细胞，即湿菌体。将湿菌体重悬于10mg/LPFOA溶液中，并使最终菌体浓度达到1g干菌体/L(将湿菌体重悬于不含PFOA的超纯水中作为空白对照)。使用0.1M的NaOH或HCl溶液将含菌液的PFOA溶液的pH迅速调整至3.0，添加少量的NaOH或HCl(少于0.5ml)其离子强度对PFOA吸附的影响可以忽略。随后将装有100ml样液的250ml锥形瓶置于37℃、150rpm摇床培养，6h后取样测定，2次平行试验取平均值。
PFOA吸附量的测定：吸附实验后，样液在8000r/min离心5min，并用0.22μm的水膜过滤，PFOA浓度用具有Waters SYNAPT MS系统的UPLC-MS测定，采用Acquity UPLC BEH c18柱(2.1×100mm，1.7μm，Waters Co.)，柱温35℃，进样量1μL。用100％(v/v)的乙腈溶液(溶液A)和0.1％(v/v)甲酸水溶液(溶液B)作为洗脱液，进行梯度清洗，流速是0.3mL/min。
表1 梯度洗脱条件
| t/min | 0-0.5 | 0.5-5.0 | 5.0-7.0 | 7.0-7.5 |
| 溶剂A比例 | 70％ | 70-100％ | 100％ | 100-70％ |
质谱条件：电离源为ESI源；MRM检测；MS+检测；Capillary(毛细管)；3.0kV；Conc(椎体)：40.00V；Source Temperature(放射源温度)：120℃；Desolvation(去溶剂化)温度：400℃；Conc Gas Flow：50L/h；Desolvation Gas Flow：700L/h.气体流速为0.1ml/min；质子比扫描范围：100-2000；扫面时间1s，间隔0.061s。结果用MassLynxV4.1(Waters公司)分析；根据吸附前后PFOA的浓度差异计算乳酸菌对PFOA的吸附量。测定结果列于图1，CCFM1053对10mg/L的PFOA的吸附率为67.5％±1.2％。
实施例2：布氏乳杆菌CCFM1053能显著改善PFOA暴露小鼠脾脏萎缩6周龄雄性C57BL/6J小鼠50只，适应环境一周后，根据体重随机分为五组：对照组、模型组、槲皮素干预组、布氏乳杆菌CCFM1053干预组、LGG干预组，每组含10只小鼠，动物分组及处理方法见表2
表2 动物实验分组及处理方法
实施例2中的小鼠于第13天称体重，随后安乐处死，取出脾脏称湿重以计算脏器系数，按以下公式计算小鼠脾脏的脏器系数：
脾脏脏器系数＝脾脏湿重/安乐死前小鼠体重
实验结果如图2所示，结果表明服用布氏乳杆菌CCFM1053能够显著逆转由于PFOA染毒造成的小鼠脾脏萎缩。
实施例4：布氏乳杆菌CCFM1053能显著降低PFOA暴露小鼠血清中ALT、AST和γ-GT的水平
取实施例2中的血清，采用全自动生化分析仪检测血清中ALT、AST和γ-GT的含量。ALT主要存在于肝细胞原浆的可溶部分，ALT活性升高提示肝细胞遭到破坏，细胞膜通透性增强。AST主要存在于肝细胞线粒体中，AST活性提高提示线粒体损伤。实验结果表明(图3)，服用布氏乳杆菌CCFM1053能够显著降低PFOA暴露小鼠血清中ALT、AST和γ-GT的含量。表明服用布氏乳杆菌CCFM1053能够显著缓解PFOA造成的小鼠肝细胞膜结构和功能的损伤。
实施例5：布氏乳杆菌CCFM1053能显著降低PFOA暴露小鼠肝脏中MDA和GSH的水平
取实施例2中的小鼠肝脏制成10％匀浆，采用购买自南京建成研究所的试剂盒检测肝脏中MDA和GSH的水平。GSH是体内重要的抗氧化酶，对ROS具有重要的清除作用。MDA是脂质过氧化过程中ROS的终产物，可直接反应脂质过氧化的水平。实验结果表明(图4)，服用布氏乳杆菌CCFM1053能够显著降低PFOA暴露小鼠肝脏中MDA和GSH的含量。说明布氏乳杆菌CCFM1053对PFOA造成的肝脏氧化应激损伤能起到有效的改善效果。
实施例3：布氏乳杆菌CCFM1053能够显著降低PFOA暴露小鼠血清中TNF-α的含量
实施例2中的小鼠于第13天安乐处死。收集血清，3000g离心15min获得血清，用ELISA试剂盒检测血清中TNF-α的含量。实验结果表明服用布氏乳杆菌CCFM1053能显著改善PFOA染毒造成的小鼠免疫损伤(图5)。
实施例6：布氏乳杆菌CCFM1053能显著降低PFOA暴露小鼠肠道中的丰度Alobaculum属的丰度，提高拟杆菌属(Bacteroides)和Eubacteriaceae科丰度，改善PFOA暴露造成的肠道紊乱，减少肝病的发生
取实施例2中小鼠第12天的新鲜粪便，采用MP的粪便试剂盒提取小鼠粪便样品中总DNA。具体操作步骤如下主要参照试剂盒说明书进行。以小鼠粪便基因组为模板，以上游引物520F(5′-AYTGGGYDTAAAGNG-3′)、下游引物802R(5′-TACNVGGGTATCTAATCC-3′)为引物扩增16S rDNA的V3-V4区片段，目的片段长度为247bp左右。PCR反应结束，将观察到目的条带的所有PCR样品再次进行电泳，配制2.0％琼脂糖凝胶，于120V条件下电泳40min，跑胶结束后，在紫外灯下快速进行目的条带的切割。按照QIAquick Gel Extraction Kit胶回收试剂盒说明书进行目的条带胶回收。根据Qubit DNA3.0试剂盒检测样品DNA浓度，随后根据TurSeq DNA LT Sample Preparation Kit及其说明构建文库，最后根据MiSeq Regent Kit及其说明经过Illumina Miseq测序仪上机测定。测序完成后，剔除掉序列长度＜200bp、引物序列、不能拼接的单序列，按照重叠碱基>10bp且无错配的标准拼接序列。将相似度大于97％序列定义为一个分类单元(Operational Taxonomic Unit，OTU)，通过RibosomalDatabase Project(RDP)
Bayesclassifier来确定物种。计算样品的α-多样性、β-多样性，用来评估样品的菌群多样性。其中α-多样性用chao1和shannon指数来表征，图6结果显示模型组小鼠的肠道菌群α多样性升高，说明PFOA暴露会伴随着一定程度的肠道紊乱。服用布氏乳杆菌CCFM1053能明显降低肠道菌群的α多样性，改善肠道紊乱情况。
此外，图7结果显示，服用布氏乳杆菌CCFM1053还能显著提高PFOA染毒小鼠中拟杆菌属(Bacteroides)和Eubacteriaceae科的丰度。拟杆菌属(Bacteroides)又称类杆菌属，是拟杆菌科的一属，为革兰氏染色阴性、无芽孢、专性厌氧的小杆菌。拟杆菌属正常寄居于人和动物的肠道、口腔、上呼吸道和生殖道。拟杆菌是人和动物体内大量存在的正常菌群，约占成年个体肠道菌群的1/4以上。是肠道细菌的营养来源；能够调节多种宿主基因的表达，包括那些涉及营养吸收，黏膜屏障强化和血管因子生成的基因；激活T细胞依赖性免疫应答；影响潘氏细胞蛋白的表达；限制病原体在胃肠道的定植。而Eubacteriaceae与肝性脑病，即肝硬化中功能失调的肠-肝-脑轴的恢复有关，在严重肥胖患者的胆肠道旁路术后其丰度显著减少。服用布氏乳杆菌CCFM1053能显著降低PFOA暴露小鼠肠道中Alobaculum属的丰度，Alobaculum属丰度增加有可能作为雌性肝细胞癌风险指标之一，并且是致癌物暴露引起的宿主癌症发生前的关键变量之一。以上结果表明布氏乳杆菌CCFM1053在缓解PFOA毒性的基础上，还同时具备调节肠道菌群、调节免疫及肠道屏障、减少肝病的发生。
实施例7：布氏乳杆菌CCFM1053对小鼠便秘的缓解作用
SPF级雄性BALB/c小鼠40只(20-25g)，随机分为5组：空白对照组、便秘模型对照组、布氏乳杆菌CCFM1053干预组、植物乳杆菌对照组和酚酞治疗对照组，每组含小鼠10只。
将布氏乳杆菌CCFM1053冻干菌粉重悬于脱脂乳粉中，制成浓度为4.0×109CFU/mL的菌悬液。实验前14天每天给干预组小鼠灌喂制备的浓度为4.0×109CFU/mL的布氏乳杆菌CCFM1053脱脂乳悬液0.25mL，植物乳杆菌组灌胃等量的L.plantarum ST-III，其余3组灌喂等量的不含菌的脱脂乳。试验第15-17天，阴性对照组灌胃0.25mL生理盐水，其余四组灌胃0.25mL，1mg/mL的洛哌丁胺溶液，确保小鼠洛哌丁胺的灌胃量为10mg/kgBW。
灌胃结束1h后，阴性对照组和便秘模型对照组灌胃脱脂乳，布氏乳杆菌CCFM1053干预组小鼠灌喂制备的浓度4.0×109CFU/mL的布氏乳杆菌CCFM1053 0.25mL，酚酞治疗对照组灌胃0.25mL，7mg/mL的酚酞溶液，确保小鼠酚酞灌胃量为70mg/kgBW。植物乳杆菌组灌胃0.25mL，4.0×109CFU/mL的L.plantarum ST-III。
实验期间的每天收集小鼠粪便，用于小鼠粪便含水量的计算，按下式计算粪便含水量：
粪便含水量(％)＝(粪便湿重-粪便干重)/粪便湿重x100。
实验结果见图8。
第17天上午除空白对照组灌胃生理盐水，其余组均灌胃洛哌丁胺，灌胃1h后，对所有小鼠灌胃活性炭阿拉伯树胶水溶液0.25mL，然后将每只小鼠单独放置在一个干净的铺有吸水纸的不锈钢笼中，记录从灌胃活性炭开始到第一粒黑便排出的时间(min)，作为首粒排黑便时间，用于评价布氏乳杆菌CCFM1053对小鼠便秘的缓解作用，期间小鼠自由进食和饮水。(图9)
实施例8：布氏乳杆菌CCFM1053可促进高糖诱导的INS-1细胞的增殖及Maf A mRNA表达
实验分成5组：正常组(含11.1mmol/L葡萄糖的普通培养液)，高糖组(含22.2mmol/L葡萄糖的高糖培养液)，罗格列酮组(高糖培养液+80μmol/L的罗格列酮)，CCFM1053组(高糖培养液+含1*109CFU/mL CCFM1053菌液)LGG组(高糖培养液+含1*109CFU/mL LGG菌液)。
将INS-1细胞(编号：BH-AC0530)培养于RPMI-1640培养液(含11.1mmol/L葡萄糖，10％FBS，50μmol/L 2-巯基乙醇，1mmol/L丙酮酸，10mmol/L HEPES)中，并放入37℃，5％CO2的培养箱中。
CCK-8法检测细胞增殖：将状态良好的细胞消化离心并接种于96孔板上，各孔约5×103个细胞，板的周边孔不接种细胞，为防止边缘效应同时向其中加入PBS溶液。待细胞贴壁，各孔中加入含0.5％胎牛血清的RPMI-1640培养基，同步化处理24h。同步化结束，依据分组向各孔加入相应培养基培养48h，每组设三个复孔，同时设置调零孔。药物干预结束，吸去旧培养基，PBS清洗2次，加入180μL无血清培养基和20μL CCK-8溶液，孵育3-4h。孵育结束，使用酶标仪于450nm下测定各孔吸光度值。
Maf A mRNA表达的测定：Trizol法提取RNA，吸弃6孔板中原培养液，同时用预冷的PBS清洗2次，各孔中分别加入1.0mL Trizol裂解细胞并将含细胞的裂解液转至无酶EP管，移液枪吹打至无明显沉淀静置5min。向各EP管加入0.2mL三氯甲烷，剧烈震荡15s，室温放置2-3min。4℃，12000rpm离心15min，吸取上清0.4m L左右，转入到另一无酶EP管中，加入0.5mL的异丙醇，颠倒混匀，室温静置10min。4℃，12000rpm离心10min，小心弃去上清，加入1.0mL 75％乙醇并颠倒混匀。4℃，12000rpm离心5min，弃上清，室温干燥2-5分钟。加入20μLDEPC处理水溶解，保存于80℃待用。测定RNA的浓度和质量，并按照反转录试剂盒说明书进行反转录。反转录得到的cDNA进行q RT-PCR检测，其中MafA特异性引物：F:5'-atcactctgcccaccatcac-3'，R:5'-atgacctcctccttgctgaa-3'。PCR体系为：F(10μM),0.50μL；R(10μM),0.50μL；c DNA Template，1.00μL；dd H2O，3.00μL；mix，5.00μL。PCR程序：95o，2min；
(95o，30sec；60o，30sec；72o，20sec)*35；72o，5min；目的基因经过Real-time PCR检测后，采用2-△△CT法进行相对基因表达分析。先用CFX Manager软件分析各组大鼠INS-1细胞目标基因的表达量，再以正常组表达量为1，其他各组与之相比较，计算各组基因表达水平。
CCK-8法检测结果如图10所示，与正常组相比，高糖作用组细胞生长明显降低(P<0.05)，罗格列酮对照组细胞增殖较高糖组有明显增加(P<0.05)，CCFM1053组与高糖组相比细胞增殖状况也明显增加(P<0.05)。
Maf A mRNA表达情况如图11显示，高糖作用组细胞的MafA mRNA的表达量明显低于正常组(P<0.05)，而罗格列酮阳性对照组和CCFM1053组的Maf A mRNA表达量较高糖作用组明显上升(P<0.05)。
实施例9：利用本发明布氏乳杆菌CCFM1053制造含该菌的发酵食品
选用新鲜蔬菜洗净后榨汁，接着进行高温瞬间灭菌，在温度140℃下高温热杀菌2秒后，立即降温至37℃，再接入本发明制备的布氏乳杆菌CCFM1053菌剂发酵剂，使其浓度达到106CFU/mL以上，在温度4℃下冷藏保存，于是得到含有本发明布氏乳杆菌CCFM1053活菌的果蔬饮料。
利用本发明能够使用布氏乳杆菌CCFM1053发酵生产制备其他发酵食品，所述发酵食品包括固态食品、液态食品、半固态食品。所述发酵食品包括乳制品、豆制品、果蔬制品，所述乳制品包括牛奶、酸奶油、布氏；所述果蔬制品包括黄瓜、胡萝卜、甜菜、芹菜、圆白菜制品。
本发明所述布氏乳杆菌CCFM1053在体外对PFOA具有良好的吸附作用；所述布氏乳杆菌显著改善因PFOA暴露造成的小鼠脾脏萎缩；显著升高PFOA暴露小鼠血清中TNF-α含量；所述布氏乳杆菌CCFM1053显著升高PFOA暴露小鼠血清中ALT、AST、γ-GT的含量；所述布氏乳杆菌CCFM1053能够将PFOA暴露小鼠肝脏中MDA的含量降低到正常水平，并降低了GSH活性。明显改善肠道菌群紊乱，降低肠道中Alobaculum属的丰度，升高拟杆菌属(Bacteroides)和Eubacteriaceae科的丰度，减少肝病的发生。所述布氏乳杆菌CCFM1053能显著提高便秘小鼠的粪便含水量和首粒黑便排出时间，缓解小鼠的便秘情况。布氏乳杆菌CCFM1053还能够提高高糖作用下INS-1细胞的增殖和MafA基因的表达、缓解PFOA相关糖尿病。
应说明的是，以上实施例仅用以说明本发明的技术方案而非限制，尽管参照较佳实施例对本发明进行了详细说明，本领域的普通技术人员应当理解，可以对本发明的技术方案进行修改或者等同替换，而不脱离本发明技术方案的精神和范围，其均应涵盖在本发明的权利要求范围当中。
Claims (5)
1.布氏乳杆菌（Lactobacillus buchneri）CCFM1053，保藏编号为GDMCC No：60651。
2.一种发酵食品，其特征在于：所述发酵食品为使用如权利要求1所述的布氏乳杆菌CCFM1053发酵生产制得，所述发酵食品包括固态食品、液态食品和半固态食品。
3.如权利要求2所述的发酵食品，其特征在于：所述发酵食品包括乳制品、豆制品和果蔬制品，所述乳制品包括牛奶、酸奶油和干酪；所述果蔬制品包括黄瓜、胡萝卜、甜菜、芹菜和圆白菜制品。
4.如权利要求1所述的布氏乳杆菌CCFM1053在制备缓解PFOA的毒性作用、缓解便秘的药物中的应用。
5.权利要求2或3所述的发酵食品在制备辅助缓解PFOA毒性、缓解便秘的保健食品的应用。
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910575089.7A CN110226630B (zh) | 2019-06-28 | 2019-06-28 | 缓解pfoa毒害作用的多功能布氏乳杆菌ccfm1053、其发酵食品及应用 |
| PCT/CN2020/098036 WO2020259564A1 (zh) | 2019-06-28 | 2020-06-24 | 缓解pfoa毒害作用的多功能乳杆菌及其应用 |
| US17/562,081 US20220152130A1 (en) | 2019-06-28 | 2021-12-27 | Multifunctional lactobacillus capable of relieving pfoa toxic effects and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910575089.7A CN110226630B (zh) | 2019-06-28 | 2019-06-28 | 缓解pfoa毒害作用的多功能布氏乳杆菌ccfm1053、其发酵食品及应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110226630A CN110226630A (zh) | 2019-09-13 |
| CN110226630B true CN110226630B (zh) | 2022-10-18 |
Family
ID=67857705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910575089.7A Active CN110226630B (zh) | 2019-06-28 | 2019-06-28 | 缓解pfoa毒害作用的多功能布氏乳杆菌ccfm1053、其发酵食品及应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110226630B (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020259564A1 (zh) * | 2019-06-28 | 2020-12-30 | 江南大学 | 缓解pfoa毒害作用的多功能乳杆菌及其应用 |
| CN110684682B (zh) * | 2019-06-28 | 2022-04-15 | 江南大学 | 缓解pfoa毒害作用的多功能干酪乳杆菌ccfm1052、其发酵食品及应用 |
| CN111109359B (zh) * | 2019-12-29 | 2022-09-02 | 江南大学 | 多功能乳酸片球菌ccfm1105、其发酵食品及应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104974968A (zh) * | 2015-07-28 | 2015-10-14 | 吉首大学 | 一种降解pfoa菌株yab-3及其应用 |
| CN105462887A (zh) * | 2015-12-23 | 2016-04-06 | 江南大学 | 一种具有缓解pfoa毒害功能的植物乳杆菌及其应用 |
-
2019
- 2019-06-28 CN CN201910575089.7A patent/CN110226630B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104974968A (zh) * | 2015-07-28 | 2015-10-14 | 吉首大学 | 一种降解pfoa菌株yab-3及其应用 |
| CN105462887A (zh) * | 2015-12-23 | 2016-04-06 | 江南大学 | 一种具有缓解pfoa毒害功能的植物乳杆菌及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110226630A (zh) | 2019-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110229769B (zh) | 缓解pfoa毒害作用的多功能发酵乳杆菌ccfm1051、其发酵食品及应用 | |
| CN110226630B (zh) | 缓解pfoa毒害作用的多功能布氏乳杆菌ccfm1053、其发酵食品及应用 | |
| CN110305820B (zh) | 鼠李糖乳杆菌ccfm1064及其应用 | |
| CN111109359B (zh) | 多功能乳酸片球菌ccfm1105、其发酵食品及应用 | |
| CN110079485B (zh) | 缓解抑郁的乳酸片球菌ccfm6432、其发酵食品及其应用 | |
| CN109481476B (zh) | 发酵乳杆菌cqpc04在制备食品或改善溃疡性结肠炎的药品中的应用 | |
| CN111117918B (zh) | 缓解pfos毒害作用的多功能戊糖片球菌ccfm1107、其发酵食品及应用 | |
| CN110964672B (zh) | 戊糖片球菌ccfm1104、其发酵食品及应用 | |
| CN109576185B (zh) | 一种具有抗流感能力的益生菌混合制剂及其应用 | |
| US20220152130A1 (en) | Multifunctional lactobacillus capable of relieving pfoa toxic effects and application thereof | |
| CN110184214B (zh) | 一种开菲尔乳杆菌及其菌制剂 | |
| CN110684682B (zh) | 缓解pfoa毒害作用的多功能干酪乳杆菌ccfm1052、其发酵食品及应用 | |
| CN114752529A (zh) | 植物乳杆菌hom3201菌株及其活菌制剂、制备方法和用途 | |
| CN111088184B (zh) | 多功能屎肠球菌ccfm1106、其饲料添加剂及应用 | |
| CN111117925A (zh) | Anaerostipes sp B2131菌及其在炎症性肠病中的应用 | |
| CN110331118B (zh) | 青春双歧杆菌ccfm1061、其发酵食品及菌剂制备方法 | |
| CN110141584B (zh) | 一种开菲尔乳杆菌m11在抑菌及作为治疗ⅱ型糖尿病药剂的活性成分的应用 | |
| CN111117916B (zh) | 缓解pfos毒害作用的多功能戊糖片球菌ccfm1103、其发酵食品及应用 | |
| CN115992059B (zh) | 一株产阿魏酸酯酶的约氏乳杆菌及其缓解溃疡性结肠炎的用途 | |
| Bobga et al. | Evaluation of the anti-diabetic potential of probiotic Lactobacillus fermentum (PRI 29) isolated from cameroonian fermented cow milk in alloxan induced diabetes type-1 mice model | |
| WO2019174002A1 (zh) | 戊糖片球菌ccfm1012、其发酵食品及其在制备拮抗空肠弯曲杆菌感染药物中的应用 | |
| CN110141583B (zh) | 一种开菲尔乳杆菌m3在抑菌及作为治疗ⅱ型糖尿病药剂的活性成分的应用 | |
| CN114533768A (zh) | 乳酸杆菌益生菌CGMCC No.1.13855在制备糖尿病治疗药物中的应用 | |
| CN114410532A (zh) | 一株降低血浆氧化三甲胺和盲肠三甲胺水平的长双歧杆菌及其应用 | |
| CN110144311B (zh) | 一种开菲尔乳杆菌及其菌制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |